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Inflammation is a pivotal pathological factor in colorectal cancer (CRC) initiation and progression, and
modulating this inflammatory state has the potential to ameliorate disease progression. NR4A receptors
have emerged as key regulators of inflammatory pathways that are important in CRC. Here, we have
examined the effect of NR4A agonist, Cytosporone B (CsnB), on colorectal tissue integrity and its effect on
the inflammatory profile in CRC tissue ex vivo. Here, we demonstrate concentrations up 100 mM CsnB did
not adversely affect tissue integrity as measured using transepithelial electrical resistance, histology and
crypt height. Subsequently, we reveal through the use of a cytokine/chemokine array, ELISA and qRT-PCR
analysis that multiple pro-inflammatory mediators were significantly increased in CRC tissue compared
to control tissue, which were then attenuated with the addition of CsnB (such as IL-1b, IL-8 and TNFa).
Lastly, stratification of the data revealed that CsnB especially alters the inflammatory profile of tumours
derived from males who had not undergone chemoradiotherapy. Thus, this study demonstrates that
NR4A agonist CsnB does not adversely affect colon tissue structure or functionality and can attenuate the
pro-inflammatory state of human CRC tissue ex vivo.
© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Colorectal cancer (CRC) is one of the most common causes of
cancer-related morbidity and mortality worldwide, with an in-
crease in CRC incidence in both sexes, particularly in those under
the age of fifty [1]. Multiple life-style risk factors contribute to its
pathogenesis including diet and smoking [1]. Additionally, in-
flammatory processes are known to play a pivotal role in the
pathogenesis of CRC, both its initiation and progression [2]. Thecine, University College Dublin, Du
Vincent’s University Hospital, Dub
ter), daniel.crean@ucd.ie (D. Crean
r Inc. This is an open access articlnuclear orphan receptor family 4A (NR4A), have emerged over the
past decade as a key regulators of multiple processes such as
inflammation, apoptosis, metabolism, stress response, differentia-
tion and proliferation [3,4]. Recently molecules tomanipulate these
receptors have been described, and although work is in its infancy,
they show promise as a therapeutic approach for treating inflam-
matory disease, having the capacity to concurrently repress pro-
inflammatory processes and activate resolution pathways [4e6].
One of the first described natural agonists for NR4A1 wasblin, Ireland
lin, Ireland
).
e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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structural footprinting shows it can also bind NR4A2 [4,7]. While
the biological relevance of such binding remains to be explored,
such studies highlight the potential cross over of NR4A agonists.
Recently the modulation of NR4A1 using CsnB has been shown to be
protective in inflammatory diseases of the gut [3]. Moreover, CsnB
also has anti-fibrotic actions inmice [8]. The role of NR4A1 in cancer
remains unclear, with some studies showing it to be pro-oncogenic,
while it was protective/tumour suppressing in other studies [9].
However, the role of NR4A1 agonism on inflammatory activation in
human CRC remains unexplored. In this studywe have exposed CRC
tissue ex vivo to CsnB and examined the impact on inflammatory
outputs using array, quantitative ELISA and gene expression anal-
ysis. Here, we reveal CsnB attenuates production of inflammatory
mediators in CRC tissue ex vivo, and, moreover, the attenuationwas
even more pronounced in males that had not undergone chemo-
radiotherapy. This study, to the best of our knowledge, is the first
examining the effect of CsnB on CRC tissue ex vivo, and as such
contributes significantly to the understanding of the efficacy of
NR4A agonist CsnB on CRC.
2. Materials and methods
2.1. Patient recruitment
This study was approved by the Ethics Committee of St. Vin-
cent’s University Hospital, Dublin, and in accordance with Inter-
national guidelines and Helsinki Declaration principles. Patients
diagnosed with colorectal cancer and already undergoing surgical
excision of tumour were recruited prospectively between
September 2016 and April 2019. All patients (n¼ 33), aged between
39 and 88 years old, provided written informed consent and their
demographic data including sex, age, location of tumour, and
whether they had chemoradiotherapy prior to resection were
noted and summarised in Supplemental Tables 1-3.
2.2. Tissue specimen preparation
Following colorectal resections, colonic human specimens
(normal and tumour) were placed in 50ml conical flasks containing
RPMI 1640 GlutaMax media (Life Technologies), and transported to
the laboratory (total-time 15 min). Normal colonic tissues were
pinned luminal side up on the dissection board allowing for the
dissection of circular and longitudinal smooth muscle from colonic
mucosae. The stripped human normal colonic mucosae, and
tumour specimens, were cut into 200 mg sections (Initial optimi-
sation experiments revealed 200 mg to be the optimumweight for
reliable data collection, data not shown), and added to a 12 well
plate and treated as detailed in figure legends. Following treat-
ments, media was removed and stored at 20 C until ELISA and
Human XL Cytokine/Chemokine array analysis, some tissue was
placed in RNAlater and stored at 80 C for further RNA extraction,
cDNA synthesis and qRT-PCR analysis.
2.3. Ussing chamber and histological processing
Muscle stripped colonic mucosae were mounted onto the
Ussing chambers (0.63 cm2 window) and maintained in a
temperature-controlled carbogenated (5% CO2, 95% O2) Krebs-
Henseleit (KH) buffer for a period of 3 h. Each half of the cham-
bers was filled with 5 ml kH and continuously mixed by gassing.
After an equilibration period of 40e45min,100 mMCsnBwas added
to the apical compartment, the DMSO concentration did not exceed
0.1%. Baseline potential difference (PD, mV), short circuit current
(Isc, mA.cm2) were measured and TEER (U.cm2) was calculated by180Ohm’s Law. Data is shown here as percentage of time 0 for each
treatment to account for any variability in basal TEER (U.cm2)
values resulting from individual tissue in different chambers over
the course of the experiments. At the end of the 120min treatment,
stimulation of an Inward short-circuit current (Isc) with carbachol
(CCh) (0.1e10 mM) was used as a functionality assay. At the end of
the Ussing experiments, mounted tissues were then formalin-fixed
(10%) and processed (Tissue-Tek® VIP, Sakura) overnight and
embedded in wax. 5 mM section were cut (Leica microtome),
mounted on slides, and stainedwith haematoxylin and eosin (H&E)
stains. The slides were visualised using a light microscope and
images were taken at 4x and 10x magnification with a high-
resolution camera (Olympus BX43) and Image-Pro ® Plus version
software (Media Cybernetics Inc., USA).2.4. Cytokine/chemokine array
105 human cytokines, chemokines were evaluated using a
Proteome Profiler Assay Human XL Cytokine Array Kit (R&D Sys-
tems, Minneapolis, MN, USA) as per manufacturer’s instructions.
Membranes were then exposed in the same frame to X-ray film for
1e10 min. The pixel densities on the developed X-ray film selected
were analysed using a transmission mode scanner and Image J®
analysis software.2.5. ELISA
Medium from treated human colonic tissue specimens (normal
and tumour) was centrifuged briefly to eliminate tissue debris, and
ELISA was performed for IL-8, MCP-1, and IL-1b as per manufac-
turer’s instructions (#431504, #438804, #437004 respectively).
200 mg of tissue was used per treatment and values that varied, on
occasion, were normalised to 200 mg post ELISA analysis. Tumour
tissue below the weight of 100 mg was not used.2.6. Real-time quantitative reverse transcription PCR (qRT-PCR)
RNA was extracted from ex vivo tissues using the GenElute
Mammalian Total RNA Miniprep kit as per manufacturer’s in-
structions (Sigma-Aldrich). cDNA synthesis and qRT-PCR was per-
formed as previously described [10]. Primer pair sequences used
are detailed in Supplemental Table 4. Relative expression/abun-
dance levels of target gene transcripts were identified using qBase
plus software (Biogazelle, Ghent University, Belgium) with
adequate reference target determined using GeNorm Analysis
(Supplemental Table 5).2.7. Data presentation and statistical analysis
Results were analysed using GraphPad Prism 6 (GraphPad, San
Diego, USA). All data is presented as mean ± standard error of the
mean (SEM). A minimum of three individual n numbers (unless
otherwise stated) were used. Statistical analysis was performed
using one-way analysis of variance (ANOVA) followed by Tukey’s
post-hoc test for cell line experiments (Supplemental Figure 1), and
a post-hoc Dunnett’s test for TEER experiments (Figure a,b). An
unpaired Student’s t-test and Mann-Whitney test were used for
comparing crypt height and gene expression data (Fig. 1e)
(Fig. 3cef), while a Wilcoxon matched-pairs signed rank test was
used for ELISA analysis (Fig. 3a,b,c) (Fig. 4) (Supplemental
Figure 2,3). Statistical significance was considered when
*p < 0.05, **p < 0.01 and ***p < 0.001. NS¼Not significant. Some p-
values (p) are also included.
Fig. 1. The effect of Cytosporone B (CsnB) on human colorectal tissue (ex-vivo) integrity and functionality. a.) Non-cancerous colon tissue was mounted on an Ussing chamber.
Tissue was then left untreated, treated with DMSO (0.1%) (vehicle control) or CsnB (100 mM) for 120 min. During the experiment baseline potential difference and short circuit
current were measured. At the end of the experiment TEER was calculated by Ohm’s law. Data are expressed as percentage of TEER at time 0hr ± SEM. b) At the end of the TEER
experiment Carbachol was added at time 0 (107mM), and then every 5 min thereafter the concentration was increased with the addition to the 106mM, 105mM, and 104mM.
Data are expressed as raw values representing Inward Short circuit current (ISc) in mA ±SEM. c.) Tissue was fixed and sectioned for histological analysis. Microscopic images of H&E
stained slides at 4x magnification were taken using Olympus BX43 microscope (scale bar 150 mm). d) This is an example of how the crypt height was then calculated (green line) in
mm. Olympus BX43 microscope was used and Image-Pro Premier 9.2 (Media Cybernetics) was utilised to calculate the crypt height. e) Bar graph representing crypt height calculated
from 4 individual crypts from 3 separate sections in each treatment group. Data was expressed as mm ±SEM. (For interpretation of the references to color in this figure legend, the
reader is referred to the Web version of this article.)
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3.1. CsnB does not adversely affect human colorectal tissue integrity
and functionality ex vivo
Preliminary studies using in vitro cell lines Caco-2 and THP-1
examined the effect of CsnB at various concentrations on cell
viability. Supplemental Fig. 1a-h demonstrates positive control
Etoposide significantly reduced metabolic activity of both cell lines,
as measure using MTT and resazurin assays, and increases caspase
3/7 activity, both indirect and direct measurements of viability.
While examination of the assays as awhole, indicate that CsnB at all
concentrations up to 100 mM does not adversely affect viability
(Supplemental Fig. 1a-h). Subsequently, we exposed non-cancerous
colonic tissue to 100 mMCsnB, as selected from in vitro experiments,
and examined gut integrity using established methods [11]. No
changes in transepithelial electrical resistance (TEER) were
observed between groups (Untreated control, control with DMSO
(0.1%) (vehicle control for CsnB), and tissue exposed to 100 mM
CsnB) over 120min, indicating that 100 mMCsnB does not adversely
alter colonic tissue integrity (Fig. 1a).
To confirm functionality of colonic tissue, an Isc was evoked by181carbachol at varying concentrations after the 120 min Ussing
experiment. A concentration response relationship was observed
with increasing concentrations of carbachol in all groups, indi-
cating that CsnB did not adversely affect tissue functionality
(Fig. 1b). Lastly, histological analysis of this tissue showed no overt
changes in architecture/histology, or crypt height, across all treat-
ments (Fig. 1c,d,e).
3.2. CsnB attenuates pro-inflammatory mediators from colorectal
tumours ex vivo
Having established CsnB did not adversely affect colonic tissue
integrity or functionality we examined the affects it had on in-
flammatory output from CRC tissue. A cytokine/chemokine array
was then performed using media collected at 8 h from vehicle-
treated control colon tissue, untreated tumour tissue, tumour
tissue þ100 mM CsnB and tumour tissue þ20 mM CsnB for 8 h. For
analysis, media from four experiments was pooled per treatment to
increase reliability of the data output. Supplemental Table 6 illus-
trates the raw pixel values of the 105 inflammatory mediators
measured. 35 targets were increased by two-fold in tumour tissue
compared with ‘normal’ control tissue and subsequently decreased
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100 mM or both). TNFa was included for further analysis as it is a
well established NR4A target, albeit it is increased only 1.92 fold
from tumour compared to normal tissue, while decreased 2.05 with
the addition of CsnB (20 mM). These 36 targets are highlighted in
yellow on Supplemental Table 6. Fig. 2a shows the raw array image
following initial ImageJ analysis with positive control (internal
array control), negative control (internal array control) and some
relevant targets, IL-8, MCP-1 and IL-1b. Fig. 2b shows a heatmap
displaying the 36 targets described above. Circles beside each target
identify those that have been previously shown in the literature to
be altered/regulated by NR4A1 (Blue circle), NR4A2 (Red circle) and
NR4A3 (Orange circle) (Fig. 2c), [12e23]. Fig. 2d illustrates the fold
over normal untreated control tissue values for these 16 targets,
taken from Supplemental Table 6.
The results of the cytokine/chemokine array identified targets of
interest which were then analysed and validated using individual
ELISAs and gene expression. Fig. 3aec shows ELISA data for IL-8,
MCP-1 and IL-1b. IL-8 was included as it is a well established
NR4A target, a pivotal cytokine in CRC, albeit it was not identified
from the array as it displayed high/saturated pixel density in all
treatments. However, ELISA analysis revealed that both IL-1b and
IL-8 were significantly secreted from tumour tissue compared to
control tissue, while no significant changes were observed in MCP-
1 (Fig. 3aec). Although IL-8 and IL-1b secretion was maintained
significant in tumour tissue treated with CsnB compared to un-
treated control a trend toward a reduced concentration of secreted
protein was observed, and more pronounced in IL-1b. Next weFig. 2. The effect of Cytosporone (CsnB) on cytokines/chemokines secretion from huma
without 20 mM and 100 mM Cytosporone B (CsnB) (n ¼ 4) were incubated for 8hrs in a tiss
cytokine/chemokine array was performed for 105 inflammatory targets and internal positive
analysis. Each dot (in duplicate) represents one target. This image shows the membranes (U
highlighting the areas of the positive control, negative control, and key targets of interest,
supplemental table 6), displayed here is a heat map representing 35 targets identified in th
control tissue (N), which were subsequently decreased greater than 2-fold with the addition
in this analysis and the rationale for this is explained in the manuscript). Coloured circles bes
Red ¼ NR4A2 and Orange ¼ NR4A3). 3c) A Venn diagram represents these targets and how
NR4A family members. 3d) Raw pixel density of targets in part c are shown as fold over untre
interpretation of the references to color in this figure legend, the reader is referred to the
182examined the gene expression profile of targets IL-8, MCP-1 and
also TNFa. MCP-1 gene expression confirms the ELISA data showing
no significant changes in any treatments, while both IL-8 and TNFa
displayed significant increases in gene expression in tumour tissue
compared to untreated control tissue, and this significance was
attenuatedwith increasing concentrations of CsnB (Fig. 3def). Gene
expression was not performed for IL-1b given it is processed pri-
marily post-transcriptionally [24]. Thus, taken together, data here
supports that CsnB can attenuate inflammatory mediators in CRC
tissue ex vivo.3.3. Stratification of data reveals CsnB may affect CRC dependent on
sex and whether the tumour was exposed to chemoradiotherapy
We next stratified the ELISA data based on sex, location, che-
moradiotherapy treatment yes/no, sex with chemoradiotherapy
treatment yes/no for IL-8, MCP-1 and IL-1b. Stratifying the ELISA
data allowed for statistical analysis given the fact that comparable
samples sizes were present in most of the stratifications. Fig. 4
shows the stratification data of interest discussed here, while
other stratification data is shown in Supplemental Fig. 2 and 3. Of
note, CsnB affected IL-8 and IL-1b levels from tumours that were
derived from males compared to females, colon versus rectum and
those that did not receive chemoradiotherapy versus had chemo-
radiotherapy, separately (Fig. 4a,b,c). When combining some of the
stratifications, a reduction in IL-8 and IL-1b secretion following
treatment with CsnB ex vivo was observed in males who had not
undergone chemoradiotherapy versus those that had, albeit notn colorectal cancer tissue ex vivo. Non-cancerous colon and tumour tissue (T) with/
ue culture incubator. Media was removed from 4 separate experiments, pooled and a
/negative controls. a.) Dot plot images of the array are displayed post Image J software
ntreated normal, Untreated Tumour, Tumour þ 100 mM CsnB, Tumour þ 20 mM CsnB)
IL-8, MCP-1, and IL1b. 3b) Following pixel density analysis using image J analysis (See
e array to be greater than 2-fold increase in tumour (T) compared to untreated normal
of either 20 mM or 100 mM CsnB (Tþ20 and Tþ100 respectively) (TNFa is also included
ide targets highlight those identified from the literature as NR4A targets (Blue ¼ NR4A1,
many were identified in the literature to have been regulated by all three, two or one
ated normal control tissue in treatments T, Tþ20 (mM CsnB) and Tþ100 (mM CsnB). (For
Web version of this article.)
Fig. 3. The effect of Cytosporone B (CsnB) on IL-8, MCP-1, IL-1b and TNFa levels from colorectal cancer tissue ex vivo. a-f) Tumour tissues (T) were treated with/without CsnB
(100 mM, a-c) (4, 20 and 100 mM, d-f) alongside untreated non-cancerous control tissue (N) for 8hrs, followed by ELISA of the media for IL-8, MCP-1, and IL-1b (aec) and RNA
isolation followed by qRT-PCR for IL-8, MCP-1, TNFa and housekeeping genes H3F3A and YWHAZ (def). Data were expressed as pg/ml ±SEM (a) and raw CNRQ values ± SEM (b)
(sample numbers are written under each treatment on the graph itself).
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and e). Regarding MCP-1 stratification, colon derived tumours
versus rectum displayed enhancedMCP-1 secretion, which trended
toward an attenuationwith by CsnB, albeit not significantly (Fig. 4f).
Thus, following stratification, CsnB addition displays a trend toward
a more pronounced reduction in IL-8 and IL-1b secretion from CRC
tissue in males that have not undergone chemoradiotherapy.
4. Discussion
Multiple studies have suggested anti-inflammatory effects of
the NR4A agonist CsnB in various models of inflammatory disease
[3,8,25]. This study, to our knowledge, is the first to investigate the
effects of CsnB on human CRC tissue ex-vivo, examining both
toxicity and inflammatory outcome. The range of concentrations
CsnB used did not adversely affect cell or tissue viability and
functionality as measured using the experimental approaches uti-
lised herein. While some studies support our in vitro viability
findings [26,27], it is important to note others have shown CsnB at
concentrations of 100 mM to be toxic to in vitro cells, albeit we can
conclude CsnB associated toxicity appears to be cell-type specific
[5,7,28]. Regarding colon tissue, CsnB up to concentrations of
100 mM does not adversely affect tissue integrity/functionality as
measured using the Ussing chamber and subsequent treatment
with carbachol. Moreover, CsnB did not overtly alter human colonic
crypt height, which is supported by previous work using Nurr77þ/
þ, Nurr77/ mice models treated with CsnB and displaying no
change in crypt height [3].
We then examined what affect CsnB would have on the in-
flammatory output from CRC tissue. Array analysis revealed 35
targets whichwere 2-fold higher in CRC tissue compared to normal,183which were then decreased 2 fold with the addition of CsnB (with
either 20 mM or 100 mM). Given that CsnB is a confirmed NR4A1
agonist, and not much data exists for CsnB, we performed an
extensive literature for the 36 targets to examine which had been
shown to be NR4A targets previously, which resulted in 16 targets
[12e23]. MCP-1, TNFa, IL-1b (identified by the array), and the well
established NR4A target IL-8, were focused on in this current study
as they are known to not only be NR4A1 targets but also play a
substantial role in CRC in terms of stimulating tumour growth,
metastasis and chemoresistance [2,29]. Gene expression analysis
and/or ELISA reveals that the addition of CsnB resulted in a trend
towards or in some cases a significant reduction in IL-8, IL-1b and/
or TNFa. Additionally, stratifying the ELISA results revealed that
CsnB seemed to have a more pronounced effect at attenuating IL-8
and IL-1b from males who had no chemoradiotherapy prior to
resection. The sex-specific effects of CsnB have not been reported to
our knowledge, while sex differences in NR4A1 KO mice have [30].
Several other studies revealed sex-specific differences in colorectal
cancer incidence, tumour location, stage at diagnosis, andmortality
rates [31]. The sex-specific impact on CRC is complex, from initia-
tion right through to treatment, and although the data collected
here highlights a potential sex-specific effect of CsnB in CRC, it does
not allow for simple conclusions to be drawn at this point, but
highlights further investigation is warranted.
Taken together, the results from this study show that CsnB can
modulate multiple pro-inflammatory mediators in colorectal can-
cer tissue ex vivowith no evident cell cytotoxicity and is tolerated in
human colorectal tissue as evidenced by experimental approaches
utilised herein. These data, to the best of our knowledge, are the
first to describe an anti-inflammatory effect of CsnB on human CRC
tissue ex vivo. Bearing that in mind, further research is warranted to
Fig. 4. The effect of Cytosporone B (CsnB) on IL-8, IL-1b and MCP-1 secreted protein from patients following stratification based on sex, location, having had chemoradiotherapy or combinations thereof. ELISA data from Fig. 3,
Tumour tissues (T), T þ with CsnB (100 mM) alongside untreated non-cancerous control tissue (N) for 8hrs is shown based on a.) sex, b.f.) location, c.) having had chemoradiotherapy (Chemorad Yes) or not (Chemorad No), and
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mechanism of action of CsnB on human CRC tissue.
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